Noven's Stavzor Final Approval Anticipated In Mid-2008 After FDA Offers “Tentative Approval”
This article was originally published in The Pink Sheet Daily
Executive Summary
Valproic acid delayed release capsules gain tentative clearance for manic episodes associated with bipolar disorder and multiple seizures, including epilepsy.
You may also be interested in...
Riding On Humira Sales, Abbott Aims For Dominance In Lipid Management Market
Product launches and Humira label expansions will compensate for Depakote generics entering the market in July, CEO White says.
Riding On Humira Sales, Abbott Aims For Dominance In Lipid Management Market
Product launches and Humira label expansions will compensate for Depakote generics entering the market in July, CEO White says.
Noven/Banner Receive FDA “Approvable” Letter For Stavzor
Data requested by the agency to complete the 505(b)(2) NDA is all “non-clinical,” Noven says.